New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
09:09 EDTGILDGilead poised to be leader in all-oral HCV treatment, says Wells Fargo
After attending the EASL conference, Wells Fargo believes that Gilead's HCV treatment has multiple advantages over the competition. The firm keeps an Outperform rating on the stock.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent GILD news | >>
April 30, 2015
16:03 EDTGILDGilead raises FY15 net product sales view to $28B-$29B from $26B-$27B
Subscribe for More Information
16:01 EDTGILDGilead reports Q1 adjusted EPS $2.94, consensus $2.32
Subscribe for More Information
16:01 EDTGILDOptions Update; April 30, 2015
iPath S&P 500 VIX Short-Term Futures up 60c to 21.84. Option volume leaders: AAPL TSLA TWTR GILD FB AMZN CELG VZ KMI according to Track Data.
15:09 EDTGILDGilead May 100 weekly straddle priced for 4.5% movement into Q1
Subscribe for More Information
15:01 EDTGILDNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Visa (V), consensus 62c... Gilead Sciences (GILD), consensus $2.32... American International (AIG), consensus $1.19... Public Storage (PSA), consensus $1.93... LinkedIn (LNKD), consensus 56c... BioMarin Pharmaceutical (BMRN), consensus (53c)... Expedia (EXPE), consensus 9c... Skyworks Solutions (SWKS), consensus $1.13... FleetCor (FLT), consensus $1.40... Eastman Chemical (EMN), consensus $1.60... Western Union (WU), consensus 38c... Fluor (FLR), consensus 98c... Fortune Brands Home & Security (FBHS), consensus 32c... Envision Healthcare (EVHC), consensus 26c... Agnico Eagle Mines (AEM), consensus 10c... FireEye (FEYE), consensus (51c)... Trimble Navigation (TRMB), consensus 30c... PerkinElmer (PKI), consensus 46c... Genpact (G), consensus 25c... athenahealth (ATHN), consensus 14c... Seattle Genetics (SGEN), consensus (19c)... HEALTHSOUTH (HLS), consensus 56c... Teradyne (TER), consensus 12c... Superior Energy (SPN), consensus (5c)... Eldorado Gold (EGO), consensus 2c... Regal Entertainment (RGC), consensus 12c... JDS Uniphase (JDSU), consensus 9c... MRC Global (MRC), consensus 18c... Boyd Gaming (BYD), consensus 9c... Ruckus Wireless (RKUS), consensus 8c... Cloud Peak Energy (CLD), consensus (12c).
April 29, 2015
16:01 EDTGILDOptions Update; April 29, 2015
iPath S&P 500 VIX Short-Term Futures up 47c to 21.24 Option volume leaders: AAPL TSLA TWTR GILD FB AMZN C MCD BAC CRM BIDU WYNN according to Track Data.
15:40 EDTGILDGilead May 103 weekly straddle priced for 4.3% movement into Q1
Subscribe for More Information
April 28, 2015
08:21 EDTGILDCompetitor data favorable for Gilead, says Bernstein
Subscribe for More Information
April 27, 2015
09:37 EDTGILDBarclays healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
08:23 EDTGILDGilead coverage assumed with an Outperform at Oppenheimer
07:38 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 26, 2015
14:56 EDTGILDGilead reports 'high cure rates' for Sovaldi in genotype 2-5 hep C patients
Subscribe for More Information
April 24, 2015
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
08:33 EDTGILDGilead May weekly volatility elevated into Q1 and outlook
Subscribe for More Information
April 23, 2015
16:01 EDTGILDOptions Update; April 23, 2015
Subscribe for More Information
07:59 EDTGILDMylan launches generic sofosbuvir tablets in India
Subscribe for More Information
05:19 EDTGILDGilead Harvoni, Sovaldi demonstrate efficacy, safety
Gilead Sciences announced results from several Phase 2 clinical studies evaluating investigational uses of Harvoni and other Sovaldi-based regimens for the treatment of chronic hepatitis C virus, or HCV, infection in patients with advanced liver disease, including patients with decompensated cirrhosis, patients with fibrosing cholestatic hepatitis C and patients with portal hypertension. In SOLAR-2, 328 genotype 1 or 4 HCV patients with decompensated liver disease before liver transplantation or recurrent HCV infection following liver transplantation were randomized to receive either 12 or 24 weeks of Harvoni plus ribavirin. Ten patients were excluded from the analysis because of transplantation or because they were pre-transplantation, but not decompensated; an additional 27 of these patients have not yet reached post-treatment week 12. The most common adverse events were fatigue, anemia, nausea and headache. Overall, six patients discontinued treatment due to adverse events, five of whom had decompensated cirrhosis.
05:16 EDTGILDGilead data supports ongoing trials evaluating shortened course of therapy
Subscribe for More Information
April 22, 2015
07:07 EDTGILDEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use